Thought leadership calls for deep knowledge and insight. Driven by PharmSource’s decades of experience and evidence-based analysis, here we share industry and market insights and actionable recommendations for both buyers and sellers of bio/pharmaceutical contract services.

Territory Watch:
Look Beyond the Usual to Capture New Business

The majority of bio/pharma funding events in the U.S. during 2014 and 2015 occurred outside the high-profile hubs of the San Francisco Bay Area and Boston. However, contract research organizations (CROs) and Contract Development and Manufacturing Organizations (CDMOs) looking to capture new business will find substantial opportunities in geographically concentrated areas far beyond…

Learn more

How big is the market for…?

We often are asked the size of the market for various segments of the bio/pharma contract services industry.

In response, we’ve developed a resource page that addresses questions like:

  • Total global bio/pharma R&D spending
  • Number of NDA approvals for dose CMOs
  • Number of approved biosimilars manufactured by CMOs

To learn about the size of these market segments and others…

Learn more

Capturing CRO Opportunities in the Medical Device and Diagnostic Market

Contract research organizations (CROs) seeking to capture business in the medical device and diagnostic segment face a unique range of challenges, most prominently the lack of information shared by medical device companies during the development process. There are ways to overcome the obstacles and win contract research business in the growing medical device and diagnostic segment…

Learn more

Follow the Money to Bio/Pharmaceutical Opportunities
Spotlight on AveXis

AveXis, Inc., plans to raise $234.5 million in a secondary public offering.

What new business opportunities are most likely to surface from this? We know that they plan to use the proceeds to fund general corporate purposes, including…

Learn more

Venture Capital Funding Confirms Transition to Large Molecule Assets

As the major source of funding for early stage companies, the Venture Capital (VC) sector can be viewed as a window into tomorrow’s therapies. Although absolute VC spend on Research and Development (R&D) is dwarfed by that of the Global Pharmaceutical sector, the overall importance of early stage funding is critical for a number of reasons…

Learn more

PharmSource Coverage of ASCO 2017

Chicago hosted 30,000 American Society of Clinical Oncology (ASCO) conference visitors this weekend. You may have noticed the uptick in the PharmSource Lead Sheet recently, especially in Phase I & II studies. In fact, oncology leads hold 46% of this week’s PharmSource Lead Sheet, so be sure to…

Learn more